Navigating tarlatamab and bispecific T-cell engager therapy in small cell lung cancer: A narrative review.
Small cell lung cancer (SCLC) remains one of the most aggressive solid malignancies, characterized by early metastasis and a historically dismal prognosis once resistance to platinum-based chemotherapy develops. For decades, therapeutic progress has been stagnant, with outcomes in the relapsed setting showing limited i...